Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05959564
Other study ID # 1960782-1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 26, 2023
Est. completion date August 8, 2023

Study information

Verified date August 2023
Source University of Maryland, College Park
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this project is to test the efficacy of a chatbot intervention for reducing HPV vaccine hesitancy among African American parents. An online experiment will be conducted to test the effectiveness of the chatbot intervention with African American parents. Results of this project will inform future communication interventions for reducing vaccine hesitancy among African American parents.


Description:

The goal of this project is to test the efficacy of a chatbot intervention for reducing HPV vaccine hesitancy among African American parents. An online survey-experiment will be conducted. In the survey-experiment, participants will first answer questions related to their attitudes toward childhood vaccines and see a brief CDC message about HPV vaccine. Then they will be directed to interact with a chatbot designed to deliver personalized HPV vaccine messages (tailored to the participant's personality) or a similar chatbot with non-personalized messages. There will also be a control condition where participants will see the brief CDC message about HPV vaccine but will not interact with any chatbot. All participants will answer questions related to their attitudes toward HPV vaccination, intentions to vaccinate their children, as well as other message response measures.


Recruitment information / eligibility

Status Completed
Enrollment 456
Est. completion date August 8, 2023
Est. primary completion date August 8, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years or older - Self-identify as Black or African American - Parents of children under 18 years old - Access to computer/laptop/mobile device and the Internet Exclusion Criteria: - Under 18 years - Does not self-identify as Black or African American - Not a parent of at least a child under 18 years old - No access to computer/laptop/mobile device or the Internet

Study Design


Intervention

Behavioral:
Personalized Chatbot Intervention
In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are tailored to their personalities.
Non-Personalized Chatbot Intervention
In this intervention, participants will first see a standard CDC HPV vaccine message. After that they will be invited to interact with a chatbot designed to deliver additional HPV vaccine messages, which are not tailored to their personalities.
No Chatbot Control
In this intervention, participants will see a standard CDC HPV vaccine message only and will not interact with any chatbot.

Locations

Country Name City State
United States University of Maryland, College Park (Online Survey-Experiment) College Park Maryland

Sponsors (1)

Lead Sponsor Collaborator
University of Maryland, College Park

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Attitudes toward HPV vaccination Participants' attitudes toward HPV vaccination will be measured by seven questions such as ""The HPV vaccine is beneficial for adolescents." Immediately after the intervention
Primary Intentions toward HPV vaccination Participants' intentions toward vaccinating their children against HPV will be measured by three questions such as "I am likely to get my child/children the HPV vaccine." Immediately after the intervention
Secondary Ratings of the Chatbot Participants in the chatbot conditions will rate the chatbot on a number of characteristics such as engagingness, relevance, and trustworthiness. Immediately after the intervention
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A